A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?

Ovarian cancer is the second most important pelvic gynaecologic malignancy and nowadays still kills 80% of patients. New treatment options are mandatory. Although it has been shown that ovarian cancer is an immunogenic tumor, the possibility of developing immunotherapy has been neglected for a long...

Descripción completa

Detalles Bibliográficos
Autores principales: Coosemans, A., Baert, T., Vergote, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Universa Press 2015
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402447/
https://www.ncbi.nlm.nih.gov/pubmed/25897374
_version_ 1782367253832925184
author Coosemans, A.
Baert, T.
Vergote, I.
author_facet Coosemans, A.
Baert, T.
Vergote, I.
author_sort Coosemans, A.
collection PubMed
description Ovarian cancer is the second most important pelvic gynaecologic malignancy and nowadays still kills 80% of patients. New treatment options are mandatory. Although it has been shown that ovarian cancer is an immunogenic tumor, the possibility of developing immunotherapy has been neglected for a long time. This article focuses on the importance of the immune system in the development and progression of cancer and the possibilities and problems of dendritic cell-based immunotherapy to influence the immune system.
format Online
Article
Text
id pubmed-4402447
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Universa Press
record_format MEDLINE/PubMed
spelling pubmed-44024472015-04-20 A view on dendritic cell immunotherapy in ovarian cancer: how far have we come? Coosemans, A. Baert, T. Vergote, I. Facts Views Vis Obgyn Viewpoint Ovarian cancer is the second most important pelvic gynaecologic malignancy and nowadays still kills 80% of patients. New treatment options are mandatory. Although it has been shown that ovarian cancer is an immunogenic tumor, the possibility of developing immunotherapy has been neglected for a long time. This article focuses on the importance of the immune system in the development and progression of cancer and the possibilities and problems of dendritic cell-based immunotherapy to influence the immune system. Universa Press 2015 /pmc/articles/PMC4402447/ /pubmed/25897374 Text en Copyright: © 2015 Facts, Views & Vision http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Viewpoint
Coosemans, A.
Baert, T.
Vergote, I.
A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?
title A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?
title_full A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?
title_fullStr A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?
title_full_unstemmed A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?
title_short A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?
title_sort view on dendritic cell immunotherapy in ovarian cancer: how far have we come?
topic Viewpoint
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402447/
https://www.ncbi.nlm.nih.gov/pubmed/25897374
work_keys_str_mv AT coosemansa aviewondendriticcellimmunotherapyinovariancancerhowfarhavewecome
AT baertt aviewondendriticcellimmunotherapyinovariancancerhowfarhavewecome
AT vergotei aviewondendriticcellimmunotherapyinovariancancerhowfarhavewecome
AT coosemansa viewondendriticcellimmunotherapyinovariancancerhowfarhavewecome
AT baertt viewondendriticcellimmunotherapyinovariancancerhowfarhavewecome
AT vergotei viewondendriticcellimmunotherapyinovariancancerhowfarhavewecome

Ejemplares similares